Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Vaccines
•
Allergy & Immunology
Do you consider immunoglobulin replacement in a patient who has rapidly waning vaccine titers but does appropriately respond to revaccination?
Related Questions
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Why are influenza and COVID vaccines still recommended for patients on immunoglobulin replacement therapy?
Do patients with a PEG allergy have a contraindication to receiving mRNA vaccines?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
When do you consider lifelong AIT?
Do you start omalizumab in childbearing patients with CSU?
Do you utilize AIT for atopic dermatitis if there is no AR present?
Are you initiating/discussing peanut OIT in most children less than age 2 due to the benefits of desensitization and remission?
